LncRNA MBNL1-AS1 Represses Cell Proliferation and Enhances Cell Apoptosis Via Targeting MiR-135a-5p/PHLPP2/FOXO1 Axis in Bladder Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2019 Nov 27

PMID 31769229

Citations 23

Authors

Xiaosong Wei

Xiaoming Yang

Beibei Wang

Yang Yang

Zhiwei Fang

Chengzhi Yi

Lei Shi

Dongkui Song

Affiliations

Soon will be listed here.

Abstract

LncRNAs have been shown to play essential roles in bladder cancer (BC) progress. Our microarrays of clinical samples firstly screened that lncRNA muscleblind-like 1 antisense RNA 1 (MBNL1-AS1) was poorly expressed in BC tissues. However, its biological function in BC remains not well understood. Here we examined the clinical correlations with MBNL1-AS1 in BC patients. Then, 5673 and T24 cell lines were employed to investigate the role of MBNL1-AS1 in the proliferation and apoptosis of BC cells in vitro and in vivo. Furthermore, miR-135a-5p (miR-135a)/PHLPP2/FOXO1 axis was focused to explore its regulatory mechanism in BC. The results showed that MBNL1-AS1 was significantly downregulated in bladder tumor tissues, and associated with BC progression. In vitro, MBNL1-AS1 knockdown increased the number of viable cells and bromodeoxyuridine-positive cells, accelerated cell cycle, and dysregulated proliferative regulators (Ki67, p21, p27, and Cyclin D1) in BC cells. The apoptotic cells and the cleavages of caspase-3/9 were reduced in MBNL1-AS1-silenced BC cells. Overexpression of MBNL1-AS1 had opposite effects on BC cell proliferation and apoptosis. Moreover miR-135a was demonstrated to interact with MBNL1-AS1, and inhibiting miR-135a reversed the effects of shMBNL1-AS1 on BC cells. The downstream effectors (PHLPP2 and FOXO1) were positively regulated by MBNL1-AS1, but negatively regulated by miR-135a. Similar results were also observed in xenograft tumors. In conclusion, this study firstly suggests that MBNL1-AS1 acts as a tumor suppressor of BC by targeting miR-135a/PHLPP2/FOXO1 axis, providing a novel insight for BC diagnosis and treatment.

Citing Articles

MBNL1‑AS1 attenuates tumor cell proliferation by regulating the miR‑29c‑3p/BVES signal in colorectal cancer.

Chen W, Zhang X, Zhao Z, Che X Oncol Rep. 2023; 50(4).

PMID: 37711058 PMC: 10523431. DOI: 10.3892/or.2023.8628.

LncRNA MBNL1-AS1 Suppresses Cell Proliferation and Metastasis of Pancreatic Adenocarcinoma through Targeting Carcinogenic miR-301b-3p.

Sulidankazha C, Alidake , Lin H, He T, Han W, Chen Q Genet Res (Camb). 2023; 2023:6785005.

PMID: 36908851 PMC: 9995204. DOI: 10.1155/2023/6785005.

Transcriptome of Lung Cancer Cells Resistant to the Cytotoxic Activity of Macrophages.

Kovaleva O, Podlesnaya P, Vasileva M, Kopnin P, Balkin A, Plotnikov A Dokl Biochem Biophys. 2023; 507(1):312-317.

PMID: 36786993 DOI: 10.1134/S160767292205009X.

CircSTK39 suppresses the proliferation and invasion of bladder cancer by regulating the miR-135a-5p/NR3C2-mediated epithelial-mesenchymal transition signaling pathway.

Li Z, Wang Z, Yang S, Shen C, Zhang Y, Jiang R Cell Biol Toxicol. 2022; 39(4):1815-1834.

PMID: 36538242 DOI: 10.1007/s10565-022-09785-3.

Down-Regulation of lncRNA MBNL1-AS1 Promotes Tumor Stem Cell-like Characteristics and Prostate Cancer Progression through miR-221-3p/CDKN1B/C-myc Axis.

Liu J, Niraj M, Wang H, Zhang W, Wang R, Kadier A Cancers (Basel). 2022; 14(23).

PMID: 36497267 PMC: 9739743. DOI: 10.3390/cancers14235783.

References

Huang C, Liao X, Jin H, Xie F, Zheng F, Li J . MEG3, as a Competing Endogenous RNA, Binds with miR-27a to Promote PHLPP2 Protein Translation and Impairs Bladder Cancer Invasion. Mol Ther Nucleic Acids. 2019; 16:51-62. PMC: 6396102. DOI: 10.1016/j.omtn.2019.01.014. View

Zhang Y, Jiang W, Yang J, Huang J, Kang G, Hu H . Downregulation of lysyl oxidase-like 4 LOXL4 by miR-135a-5p promotes lung cancer progression in vitro and in vivo. J Cell Physiol. 2019; 234(10):18679-18687. DOI: 10.1002/jcp.28508. View

Li P, Xing W, Xu J, Yuan D, Liang G, Liu B . microRNA-301b-3p downregulation underlies a novel inhibitory role of long non-coding RNA MBNL1-AS1 in non-small cell lung cancer. Stem Cell Res Ther. 2019; 10(1):144. PMC: 6528355. DOI: 10.1186/s13287-019-1235-8. View

DeGeorge K, Holt H, Hodges S . Bladder Cancer: Diagnosis and Treatment. Am Fam Physician. 2017; 96(8):507-514. View

Wei X, Yang X, Wang B, Yang Y, Fang Z, Yi C . LncRNA MBNL1-AS1 represses cell proliferation and enhances cell apoptosis via targeting miR-135a-5p/PHLPP2/FOXO1 axis in bladder cancer. Cancer Med. 2019; 9(2):724-736. PMC: 6970060. DOI: 10.1002/cam4.2684. View

Albers P . Words of wisdom. Re: cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. Eur Urol. 2008; 53(1):208-9. DOI: 10.1016/j.eururo.2007.10.020. View

Brognard J, Sierecki E, Gao T, Newton A . PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell. 2007; 25(6):917-31. DOI: 10.1016/j.molcel.2007.02.017. View

Mao X, Zhang L, Huang B, Zhou S, Liao J, Chen L . Mir-135a enhances cellular proliferation through post-transcriptionally regulating PHLPP2 and FOXO1 in human bladder cancer. J Transl Med. 2015; 13:86. PMC: 4367980. DOI: 10.1186/s12967-015-0438-8. View

Peng Y, Leng W, Duan S, Hong M . Long noncoding RNA BLACAT1 is overexpressed in hepatocellular carcinoma and its downregulation suppressed cancer cell development through endogenously competing against hsa-miR-485-5p. Biomed Pharmacother. 2019; 116:109027. DOI: 10.1016/j.biopha.2019.109027. View

10.

Zhao X, Wang D, Ding Y, Zhou J, Liu G, Ji Z . lncRNA ZEB1-AS1 promotes migration and metastasis of bladder cancer cells by post-transcriptional activation of ZEB1. Int J Mol Med. 2019; 44(1):196-206. PMC: 6559313. DOI: 10.3892/ijmm.2019.4187. View

11.

Li X, Wang Z, Li L, Zhao G, Yu S . Downregulation of the long noncoding RNA MBNL1-AS1 protects sevoflurane-pretreated mice against ischemia-reperfusion injury by targeting KCNMA1. Exp Mol Med. 2018; 50(9):1-16. PMC: 6123634. DOI: 10.1038/s12276-018-0133-y. View

12.

Jiang G, Huang C, Li J, Huang H, Jin H, Zhu J . Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145. Mol Cancer Ther. 2017; 16(5):924-935. PMC: 5418086. DOI: 10.1158/1535-7163.MCT-16-0631. View

13.

Yu H, Xu Q, Liu F, Ye X, Wang J, Meng X . Identification and validation of long noncoding RNA biomarkers in human non-small-cell lung carcinomas. J Thorac Oncol. 2015; 10(4):645-54. DOI: 10.1097/JTO.0000000000000470. View

14.

Gao T, Furnari F, Newton A . PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 2005; 18(1):13-24. DOI: 10.1016/j.molcel.2005.03.008. View

15.

Mao X, Xiao J, Li Z, Zheng Y, Zhang N . Effects of microRNA-135a on the epithelial-mesenchymal transition, migration and invasion of bladder cancer cells by targeting GSK3β through the Wnt/β-catenin signaling pathway. Exp Mol Med. 2018; 50(1):e429. PMC: 5799799. DOI: 10.1038/emm.2017.239. View

16.

Stein J, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19(3):666-75. DOI: 10.1200/JCO.2001.19.3.666. View

17.

Wu Q, Shi M, Meng W, Wang Y, Hui P, Ma J . Long noncoding RNA FOXD3-AS1 promotes colon adenocarcinoma progression and functions as a competing endogenous RNA to regulate SIRT1 by sponging miR-135a-5p. J Cell Physiol. 2019; 234(12):21889-21902. DOI: 10.1002/jcp.28752. View

18.

Li H, Sun X, Li Z, Yin Q, Pang H, Pan J . LncRNA UCA1 Promotes Mitochondrial Function of Bladder Cancer via the MiR-195/ARL2 Signaling Pathway. Cell Physiol Biochem. 2017; 43(6):2548-2561. DOI: 10.1159/000484507. View

19.

Li C, Chen Y . Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy. Curr Genomics. 2016; 16(5):319-26. PMC: 4763970. DOI: 10.2174/1389202916666150707155851. View

20.

Tian X, Zhu X, Yan T, Yu C, Shen C, Hong J . Differentially Expressed lncRNAs in Gastric Cancer Patients: A Potential Biomarker for Gastric Cancer Prognosis. J Cancer. 2017; 8(13):2575-2586. PMC: 5595087. DOI: 10.7150/jca.19980. View